Search Results

PsiOxus Therapeutics, Ltd. today announces the appointment of Howard Davis, Ph.D., as Chief Executive Officer.

Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Galera Therapeutics, Inc. announced that its Board of Directors has unanimously resolved to adopt a limited duration stockholder rights agreement to protect stockholder interests.

Tryp Therapeutics, Inc. today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have been granted a pivotal 2 cent waiver by the Australian Securities Exchange (“ASX”).

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.